To provide patients with LEMS/CMS/downbeat nystagmus access to amifampridine phosphate therapy where physicians would like to treat with amifampridine phosphate
To assess the long-term safety of amifampridine phosphate in patients with LEMS/CMS/downbeat nystagmus
Catalyst Pharmaceutical Partners, Inc
Voisin Consulting Life Sciences, Inc.
For more information about this study, please visit:
Congenital Myasthenic Syndrome: Expanded Access Study of Amifampridine Phosphate